By Dr Pranab Gyawali, Consultant Gastroenterologist (UK-trained) in Dubai
I have a patient who is about to start Tremfya, so I was looking closely at the latest data presented at the recent ECCO Crohn’s and Colitis conference.
What matters is not just whether a treatment works at the start, but whether it keeps patients well over time.
What is Tremfya (guselkumab)?
Tremfya is a biologic targeting the IL-23 pathway involved in inflammation.
What did the ECCO 2026 study show?
Patients were followed for more than two years. Around 80% of those who responded early remained in remission. No new safety concerns were identified.
Does it work for everyone?
No. Around 3 to 4 out of 10 patients may not see enough benefit, which is similar across biologics.
Why does long-term data matter?
Ulcerative colitis is a long-term condition. What matters is sustained remission and stability.
Is it safe long term?
No new safety signals were seen over more than two years.
Clinical perspective
When Tremfya works early, it appears to keep patients well over time, which is the goal of treatment.
Recommended Guides
- Ulcerative Colitis Treatment in Dubai
- Biologics for IBD in Dubai
- Inflammatory Bowel Disease Overview
Biologics & Treatment Strategy
Microbiome & Gut Health
- Gut Microbiome and Health
- Microbiome in IBD
- Ultra-Processed Foods and Gut Health
- Diet, Microbiome and IBD (Oxygen Trap)
Investigations & Procedures
If you wish to discuss this further or would like to make an appointment, please use the booking form on this page.